Anti-cytokine therapy for the treatment of graft-versus-host disease

David A. Jacobsohn, Georgia Boyce Vogelsang

Research output: Contribution to journalArticle

Abstract

Acute graft-versus-host disease (GVHD) and chronic GVHD remain the major barriers to successful hematopoietic cell transplantation. The induction of GVHD may be divided into three phases- (I) recipient conditioning, (II) donor T cell activation, and (III) effector cells mediating GVHD. Cytokines have been shown to be extremely important in the initiation and propagation of GVHD. Of note, IL-2 and TNF-α lead to cellular activation as well as local tissue damage. There has been a major development in the last few years of monoclonal antibodies that target cytokines. Drugs that target the IL-2 receptor (daclizumab and basiliximab) are now commonly used to prevent renal transplant rejection. Furthermore, drugs that target TNF-α (infliximab and etanercept) are used in rheumatoid arthritis and Crohn's disease but are also being tested for a number of other autoimmune diseases. These agents are very selective immunosuppressants that have different mechanisms of action than the calcineurin inhibitors and therefore are potentially promising for treatment or prevention of GVHD. The authors present up-to-date data regarding the use and development of anti-cytokine therapy for GVHD. The most effective approach to GVHD prevention will likely be a combination regimen where the three phases of the GVHD cascade are disrupted. Once GVHD has occurred, all three phases of the cascade are activated. Developments of combination therapy for treatment of both acute and chronic GVHD will likely yield better results than monotherapy. The numerous new treatment modalities presented should improve the outlook for acute and chronic GVHD.

Original languageEnglish (US)
Pages (from-to)1195-1205
Number of pages11
JournalCurrent Pharmaceutical Design
Volume10
Issue number11
DOIs
StatePublished - 2004

Fingerprint

Graft vs Host Disease
Cytokines
Therapeutics
Interleukin-2 Receptors
Cell Transplantation
Graft Rejection
Immunosuppressive Agents
Crohn Disease
Pharmaceutical Preparations
Autoimmune Diseases
Interleukin-2
Rheumatoid Arthritis
Monoclonal Antibodies
T-Lymphocytes
Kidney

Keywords

  • Basilimab
  • Cytokines
  • Daclizumab
  • Etanercept
  • Graft-versus-host-disease
  • Infliximab
  • Stem cell transplantation

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Anti-cytokine therapy for the treatment of graft-versus-host disease. / Jacobsohn, David A.; Vogelsang, Georgia Boyce.

In: Current Pharmaceutical Design, Vol. 10, No. 11, 2004, p. 1195-1205.

Research output: Contribution to journalArticle

@article{4636039c7ec84e4eaa7787ce59cd5344,
title = "Anti-cytokine therapy for the treatment of graft-versus-host disease",
abstract = "Acute graft-versus-host disease (GVHD) and chronic GVHD remain the major barriers to successful hematopoietic cell transplantation. The induction of GVHD may be divided into three phases- (I) recipient conditioning, (II) donor T cell activation, and (III) effector cells mediating GVHD. Cytokines have been shown to be extremely important in the initiation and propagation of GVHD. Of note, IL-2 and TNF-α lead to cellular activation as well as local tissue damage. There has been a major development in the last few years of monoclonal antibodies that target cytokines. Drugs that target the IL-2 receptor (daclizumab and basiliximab) are now commonly used to prevent renal transplant rejection. Furthermore, drugs that target TNF-α (infliximab and etanercept) are used in rheumatoid arthritis and Crohn's disease but are also being tested for a number of other autoimmune diseases. These agents are very selective immunosuppressants that have different mechanisms of action than the calcineurin inhibitors and therefore are potentially promising for treatment or prevention of GVHD. The authors present up-to-date data regarding the use and development of anti-cytokine therapy for GVHD. The most effective approach to GVHD prevention will likely be a combination regimen where the three phases of the GVHD cascade are disrupted. Once GVHD has occurred, all three phases of the cascade are activated. Developments of combination therapy for treatment of both acute and chronic GVHD will likely yield better results than monotherapy. The numerous new treatment modalities presented should improve the outlook for acute and chronic GVHD.",
keywords = "Basilimab, Cytokines, Daclizumab, Etanercept, Graft-versus-host-disease, Infliximab, Stem cell transplantation",
author = "Jacobsohn, {David A.} and Vogelsang, {Georgia Boyce}",
year = "2004",
doi = "10.2174/1381612043452569",
language = "English (US)",
volume = "10",
pages = "1195--1205",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Anti-cytokine therapy for the treatment of graft-versus-host disease

AU - Jacobsohn, David A.

AU - Vogelsang, Georgia Boyce

PY - 2004

Y1 - 2004

N2 - Acute graft-versus-host disease (GVHD) and chronic GVHD remain the major barriers to successful hematopoietic cell transplantation. The induction of GVHD may be divided into three phases- (I) recipient conditioning, (II) donor T cell activation, and (III) effector cells mediating GVHD. Cytokines have been shown to be extremely important in the initiation and propagation of GVHD. Of note, IL-2 and TNF-α lead to cellular activation as well as local tissue damage. There has been a major development in the last few years of monoclonal antibodies that target cytokines. Drugs that target the IL-2 receptor (daclizumab and basiliximab) are now commonly used to prevent renal transplant rejection. Furthermore, drugs that target TNF-α (infliximab and etanercept) are used in rheumatoid arthritis and Crohn's disease but are also being tested for a number of other autoimmune diseases. These agents are very selective immunosuppressants that have different mechanisms of action than the calcineurin inhibitors and therefore are potentially promising for treatment or prevention of GVHD. The authors present up-to-date data regarding the use and development of anti-cytokine therapy for GVHD. The most effective approach to GVHD prevention will likely be a combination regimen where the three phases of the GVHD cascade are disrupted. Once GVHD has occurred, all three phases of the cascade are activated. Developments of combination therapy for treatment of both acute and chronic GVHD will likely yield better results than monotherapy. The numerous new treatment modalities presented should improve the outlook for acute and chronic GVHD.

AB - Acute graft-versus-host disease (GVHD) and chronic GVHD remain the major barriers to successful hematopoietic cell transplantation. The induction of GVHD may be divided into three phases- (I) recipient conditioning, (II) donor T cell activation, and (III) effector cells mediating GVHD. Cytokines have been shown to be extremely important in the initiation and propagation of GVHD. Of note, IL-2 and TNF-α lead to cellular activation as well as local tissue damage. There has been a major development in the last few years of monoclonal antibodies that target cytokines. Drugs that target the IL-2 receptor (daclizumab and basiliximab) are now commonly used to prevent renal transplant rejection. Furthermore, drugs that target TNF-α (infliximab and etanercept) are used in rheumatoid arthritis and Crohn's disease but are also being tested for a number of other autoimmune diseases. These agents are very selective immunosuppressants that have different mechanisms of action than the calcineurin inhibitors and therefore are potentially promising for treatment or prevention of GVHD. The authors present up-to-date data regarding the use and development of anti-cytokine therapy for GVHD. The most effective approach to GVHD prevention will likely be a combination regimen where the three phases of the GVHD cascade are disrupted. Once GVHD has occurred, all three phases of the cascade are activated. Developments of combination therapy for treatment of both acute and chronic GVHD will likely yield better results than monotherapy. The numerous new treatment modalities presented should improve the outlook for acute and chronic GVHD.

KW - Basilimab

KW - Cytokines

KW - Daclizumab

KW - Etanercept

KW - Graft-versus-host-disease

KW - Infliximab

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=1842430919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842430919&partnerID=8YFLogxK

U2 - 10.2174/1381612043452569

DO - 10.2174/1381612043452569

M3 - Article

VL - 10

SP - 1195

EP - 1205

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 11

ER -